Bipolar Disorder is NOT a Contraindication to GLP-1 Receptor Agonists
Bipolar disorder is not listed as a contraindication in FDA labeling for any GLP-1 receptor agonist, and emerging evidence suggests these medications may actually be beneficial for psychiatric outcomes in this population.
FDA-Approved Contraindications
The only contraindications for GLP-1 receptor agonists are 1, 2:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to the medication or its components
Bipolar disorder is conspicuously absent from this list across all FDA labels for semaglutide, dulaglutide, and liraglutide.
Emerging Evidence Suggests Potential Benefit
Recent high-quality evidence indicates GLP-1 receptor agonists may actually improve psychiatric outcomes in bipolar disorder:
Semaglutide shows the strongest signal for benefit:
- A 2026 Swedish nationwide cohort study found semaglutide was associated with a 21% lower risk of psychiatric hospitalization (aHR 0.79,95% CI 0.69-0.91) and a 17% lower risk of bipolar disorder relapse (aHR 0.83,95% CI 0.69-0.99) compared to non-use periods in the same individuals 3
- Notably, this benefit was specific to semaglutide—liraglutide and dulaglutide did not show similar protective effects, suggesting this is not a class effect 3
No increased risk of psychiatric adverse events:
- A 2026 meta-analysis of 86 RCTs with 133,378 participants found no association between GLP-1 receptor agonists and psychiatric disorders overall (RR 0.96,95% CI 0.85-1.08), including specifically for bipolar disorder (RR 1.19,95% CI 0.56-2.55) 4
- In patients with severe mental illness including bipolar disorder, GLP-1 receptor agonists demonstrated acceptable tolerability with no significant difference in all-cause dropouts (RR 0.98,95% CI 0.71-1.35) 5
Clinical Approach
When prescribing GLP-1 receptor agonists to patients with bipolar disorder:
- Screen for actual contraindications (MTC history, MEN 2, hypersensitivity)—not bipolar disorder itself
- Consider semaglutide as first-line if choosing a GLP-1 receptor agonist, given the specific evidence for psychiatric benefit 3
- Monitor for mood stability as you would with any medication, but recognize these agents may actually reduce relapse risk
- Address metabolic comorbidities aggressively, as the diabetes/obesity-bipolar disorder overlap is common and these medications effectively treat both domains 5
Important Caveats
While one pharmacovigilance study reported disproportionate reporting of depressive symptoms and suicidal ideation with semaglutide in adverse event databases 6, this conflicts with the more robust within-individual cohort data showing protective effects 3, 7. Pharmacovigilance data are hypothesis-generating but cannot establish causation and are subject to reporting bias. The controlled trial evidence and within-individual cohort designs provide stronger causal inference.
The bottom line: Bipolar disorder should not prevent you from prescribing GLP-1 receptor agonists when metabolically indicated, and semaglutide may offer dual benefits for both metabolic and psychiatric outcomes.